Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, Vilas D, Tolosa E, Berg D, Warø B, Glickman A, Raymond D, Inzelberg R, Ruiz-Martinez J, Mondragon E, Friedman E, Hassin-Baer S, Alcalay RN, Mejia-Santana H, Aasly J, Foroud T, Marder K, Giladi N, Bressman S, Saunders-Pullman R.
Agalliu I, et al. Among authors: glickman a.
Mov Disord. 2019 Sep;34(9):1392-1398. doi: 10.1002/mds.27807. Epub 2019 Jul 26.
Mov Disord. 2019.
PMID: 31348549
Free PMC article.